Navigation Links
In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells
Date:7/11/2014

July 11, 2014 The increased risk of kidney injury related to the use of hydroxyethyl starch (HES) in resuscitation fluids reflects the mass of HES molecules, according to a report in Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

The "total mass of HES molecules" explains the harmful effect of HES on cultured human renal proximal tubule cells (PTCs), concludes the laboratory study by Dr Christian Wunder and colleagues of University Hospital Wrzburg, Austria. Other factorssuch as differences in the origin or molecular weight of HES solutionsappear to play little or no role in cellular-level toxicity of HES.

What Factors Affect Toxic Effects of HES on Kidney Cells?

Hydroxyethyl starch is a starch derivative that has been widely used for fluid resuscitation with volume expansion for critically ill or injured patients in shock. A growing body of evidence suggests that HES solutions may have harmful effects, including an increased risk of kidney injury and death.

In previous studies, Dr Wunder and colleagues found that HES caused impaired kidney function in animals with sepsis (severe infection). Those studies showed that HES was localized mainly in the kidney PTCs. The researchers performed a series of in-depth follow-up experiments to look at factors influencing the toxic effects of HES on cultured human PTCs.

Most of the factors assessed had no major influence on reductions in cell viability caused by HES. Cellular toxicity was unrelated to the type of "carrier" solution used in the cell cultures, the use of HES made from different origins (potato versus corn starch), or the time cells spent in culture with HES.

The toxic effects were also similar for HES solutions of different molecular weights. That's an important finding, as newer low-molecular weight HES solutions were thought to be safer than previous products. There was also no evidence
'/>"/>

Contact: Connie Hughes
Connie.Hughes@wolterskluwer.com
646-674-6348
Wolters Kluwer Health
Source:Eurekalert

Page: 1 2

Related biology news :

1. Are enough women included in medical device studies, as required by the FDA?
2. Resistant starch content of potatoes varies significantly by preparation and service method
3. Study shows that diet of resistant starch helps the body resist colorectal cancer
4. Study documents eating of soil, raw starch in Madagascar
5. Inexpensive, abundant starch fibers could lead to ouchless bandages
6. Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors
7. CNIO scientists develop technology to redirect proteins towards specific areas of the genome
8. Wyss Institute founding director Don Ingber to deliver 2014 Graeme Clark Oration
9. Turtle migration directly influenced by ocean drift experiences as hatchlings
10. Galectins direct immunity against bacteria that employ camouflage
11. Ground breaking technique offers DNA Sat Nav direct to your ancestors home 1,000 years ago
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014) Scientists at The New York Stem ... closer to creating a viable cell replacement therapy ... , For the first time, NYSCF scientists ... skin samples of patients with primary progressive multiple ... to induce these stem cells into becoming oligodendrocytes, ...
(Date:7/24/2014)... Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication ... 3 study of Zerenex (ferric citrate), the Company,s investigational ... hyperphosphatemia in patients with end-stage renal disease (ESRD) on ... with FErric CiTrate in EsrD) was published online today ... Nephrology ( JASN ). , This ...
(Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... DENVER (Feb. 21, 2013) A new study from the ... practices in Eurasia varied widely, with some graves lavish and ... don,t know why some of these burials were so ornate, ... modern humans in Europe by almost 10,000 years," said Julien ...
... SOLOMONS, MD (February 21, 2013)--Biologists Jackie Grebmeier and Lee Cooper ... Biological Laboratory have been visiting the chilly area north of ... but it,s only in the last few years that they ... summer was the highest ice retreat in the Arctic record, ...
... NY, February 20, 2013As the nations of the world ... in endangered sharks in early March, a team of ... the oceanic whitetip shark regularly crosses international boundaries. ... predator within their own maritime borders may therefore need ...
Cached Biology News:Early human burials varied widely but most were simple 2Early human burials varied widely but most were simple 3Biologists lead international team to track Arctic response to climate change 2New research on migratory behavior of oceanic whitetip sharks can help shape conservation strategies 2New research on migratory behavior of oceanic whitetip sharks can help shape conservation strategies 3
(Date:7/24/2014)... 24, 2014 2014 Deep Research ... is a professional and in-depth research report on ... Sulphate basic information, including its definition, classification, ... This research covers the international market analysis, including ... analysis covering macroeconomic environment & economic situation analysis, ...
(Date:7/24/2014)... WIRB-Copernicus Group ® ("WCG")™, the ... services for clinical research, announced today that it ... Richmond, VA -based Alliance Engineering, ... consulting firm in the United States ... – WCG Biosafety™ – will be able to ...
(Date:7/24/2014)... Toronto, Canada (PRWEB) July 24, 2014 ... for Optimizing Dose Escalation in First in Human Studies” ... to make better go/no-go decisions. , With increasing R&D ... market, pharmaceutical companies need to maximize the knowledge collected ... go/no-go decisions and improve success in late stage development. ...
(Date:7/24/2014)...  Spherix Incorporated (SPEX) -- an intellectual property development ... property, today announced that the Company will issue a ... on Monday, August 18, 2014 for shareholders. Management has ... Monday, August 18, 2014 to discuss the company,s progress ... Anthony Hayes . Following prepared remarks, ...
Breaking Biology Technology:Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2Spherix Schedules Shareholder Update Call 2
... Companies Also Sign Manufacturing and Distribution Agreement, ... 15 Ranbaxy,Pharmaceuticals Inc. (RPI), a wholly ... today that it has reached several,agreements with ... capsules. The third agreement pertains to Omeprazole ...
... Symbol: MS, EDMONTON, April 15 /PRNewswire-FirstCall/ - ... the treatment of multiple sclerosis (MS), today,announced that ... data from the Company,s on-going MAESTRO-03 U.S. pivotal ... of secondary progressive MS and,recommended that the trial ...
... 15 Emisphere,Technologies, Inc. (Nasdaq: EMIS ), ... Meeting on Thursday, May 8, 2008, at the ... New Jersey. The,meeting will begin at 10:00 a.m. ... Technologies, Inc. is a biopharmaceutical company that,focuses on ...
Cached Biology Technology:Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation 2Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation 3BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2Emisphere Technologies To Hold Annual Stockholders Meeting on May 8, 2008 2
Human SIGIRR MAb (Clone 162201)...
... 1. 1000 V, 400 mA, 100 ... constant power modes.Single-unit increments in settings ... and recalls three protocols.Outstanding choice for ... Multiphor II or GenePhor systems. Category: ...
Mouse Serpin F1/PEDF MAb (Clone 199315)...
Mouse Nodal Affinity Purified Polyclonal Ab...
Biology Products: